157 related articles for article (PubMed ID: 29979295)
1. Ultra-long-acting insulins: A review of efficacy, safety, and implications for practice.
Davis CS; Fleming JW; Malinowski SS; Brown MA; Fleming LW
J Am Assoc Nurse Pract; 2018 Jul; 30(7):373-380. PubMed ID: 29979295
[TBL] [Abstract][Full Text] [Related]
2. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Dehghani M; Sadeghi M; Barzkar F; Maghsoomi Z; Janani L; Motevalian SA; Loke YK; Ismail-Beigi F; Baradaran HR; Khamseh ME
Front Endocrinol (Lausanne); 2024; 15():1286827. PubMed ID: 38586456
[TBL] [Abstract][Full Text] [Related]
4. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
Heise T; Kaplan K; Haahr HL
J Diabetes Sci Technol; 2018 Mar; 12(2):356-363. PubMed ID: 28946756
[TBL] [Abstract][Full Text] [Related]
5. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
[TBL] [Abstract][Full Text] [Related]
6. Ultra-long-acting insulins: A review of efficacy, safety, and implications for practice.
J Am Assoc Nurse Pract; 2018 Jul; 30(7):381-382. PubMed ID: 29979296
[No Abstract] [Full Text] [Related]
7. Comparative efficacy and safety of basal insulins: A review.
Vargas-Uricoechea H; Aschner P
Diabetes Metab Syndr; 2021; 15(6):102318. PubMed ID: 34695771
[TBL] [Abstract][Full Text] [Related]
8. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
[TBL] [Abstract][Full Text] [Related]
9. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of insulin degludec.
Vora J; Cariou B; Evans M; Gross JL; Harris S; Landstedt-Hallin L; Mithal A; Rodriguez MR; Meneghini L
Diabetes Res Clin Pract; 2015 Jul; 109(1):19-31. PubMed ID: 25963320
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
12. Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine.
Weatherall J; Bloudek L; Buchs S
Curr Med Res Opin; 2017 Feb; 33(2):231-238. PubMed ID: 27764979
[TBL] [Abstract][Full Text] [Related]
13. A patient centred approach to basal insulin choice for the management of type 2 diabetes mellitus.
Kalra S; Gupta Y
J Pak Med Assoc; 2016 Mar; 66(3):360-1. PubMed ID: 26968297
[TBL] [Abstract][Full Text] [Related]
14. Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study (Kobe Best Basal Insulin Study 2).
Miura H; Sakaguchi K; Okada Y; Otowa-Suematsu N; Yamada T; So A; Komada H; Hirota Y; Kishi M; Takeda A; Tominaga Y; Nakamura T; Kuroki Y; Matsuda T; Iida K; Kajikawa M; Ohara T; Yokota K; Hara K; Tateya S; Tamori Y; Ogawa W
Diabetes Ther; 2018 Dec; 9(6):2399-2406. PubMed ID: 30341665
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study.
Suzuki J; Yamakawa T; Oba M; Nagakura J; Shigematsu E; Tamura H; Takahashi K; Okamoto Y; Sakamoto R; Shinoda M; Takano T; Kadonosono K; Terauchi Y
Endocr J; 2019 Nov; 66(11):971-982. PubMed ID: 31270291
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
Zinman B; DeVries JH; Bode B; Russell-Jones D; Leiter LA; Moses A; Johansen T; Ratner R;
Lancet Diabetes Endocrinol; 2013 Oct; 1(2):123-31. PubMed ID: 24622318
[TBL] [Abstract][Full Text] [Related]
17. Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes.
Chatterjee S; Khunti K; Davies MJ
Drugs; 2019 Feb; 79(2):173-186. PubMed ID: 30623349
[TBL] [Abstract][Full Text] [Related]
18. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
[TBL] [Abstract][Full Text] [Related]
19. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
Lajara R; Cengiz E; Tanenberg RJ
Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
[TBL] [Abstract][Full Text] [Related]
20. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
